Cargando…
Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals
BACKGROUND: Persons with assigned male sex at birth (AMAB) might wish to obtain feminization and/or demasculinization according to the person's gender identity and are therefore treated with estradiol and/or antiandrogens. AIM: The aim was to evaluate biochemical changes and side effects in AMA...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847821/ https://www.ncbi.nlm.nih.gov/pubmed/34968811 http://dx.doi.org/10.1016/j.esxm.2021.100472 |
_version_ | 1784652128900349952 |
---|---|
author | Hojbjerg, Johanne Andersen Højgaard, Astrid Ditte Hvas, Anne-Mette |
author_facet | Hojbjerg, Johanne Andersen Højgaard, Astrid Ditte Hvas, Anne-Mette |
author_sort | Hojbjerg, Johanne Andersen |
collection | PubMed |
description | BACKGROUND: Persons with assigned male sex at birth (AMAB) might wish to obtain feminization and/or demasculinization according to the person's gender identity and are therefore treated with estradiol and/or antiandrogens. AIM: The aim was to evaluate biochemical changes and side effects in AMAB individuals treated with guideline-based feminizing hormone treatment (FHT). METHODS: Medical charts of 99 AMAB individuals ≥ 18 years referred to the Center for Gender Identity; Aalborg University hospital, Denmark, between January 2017 and July 2019 were reviewed to identify adverse side effects. Furthermore, data from the laboratory information system (Labka II) were retrieved to obtain biochemical parameters. Biochemical plasma concentrations after initiation of FHT were compared to concentrations prior to FHT and to existing guidelines. OUTCOMES: After 11–19 months, 29% of the trans feminine individuals had plasma estradiol concentrations within the treatment target. RESULTS: The plasma concentration of estradiol varies greatly during FHT. Plasma levels of estrogen were within the treatment target after 11–19 months of treatment, whereas 100% had concentrations within the reference range for premenopausal cis-women. Furthermore, plasma concentrations of lipids and hematological parameters approached female reference ranges after 11 months of FHT. CLINICAL IMPLICATIONS: The target levels of plasma estradiol concentrations during FHT could be expanded, making the wanted physiological changes easier to obtain. STRENGTHS & LIMITATION: This cohort study included 99 AMAB individuals and biochemical evaluation was possible in 67 individuals. Only one individual was lost during follow-up. However, the follow-up period was limited making evaluation of long-term side effects impossible. CONCLUSION: Plasma concentration of estradiol varies greatly during guideline based FHT, making plasma estradiol levels within the target level difficult to attain. JA Hojbjerg, AD Højgaard, A-M Hvas. Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals. Sex Med 2021;10:100472. |
format | Online Article Text |
id | pubmed-8847821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88478212022-02-22 Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals Hojbjerg, Johanne Andersen Højgaard, Astrid Ditte Hvas, Anne-Mette Sex Med Original Research BACKGROUND: Persons with assigned male sex at birth (AMAB) might wish to obtain feminization and/or demasculinization according to the person's gender identity and are therefore treated with estradiol and/or antiandrogens. AIM: The aim was to evaluate biochemical changes and side effects in AMAB individuals treated with guideline-based feminizing hormone treatment (FHT). METHODS: Medical charts of 99 AMAB individuals ≥ 18 years referred to the Center for Gender Identity; Aalborg University hospital, Denmark, between January 2017 and July 2019 were reviewed to identify adverse side effects. Furthermore, data from the laboratory information system (Labka II) were retrieved to obtain biochemical parameters. Biochemical plasma concentrations after initiation of FHT were compared to concentrations prior to FHT and to existing guidelines. OUTCOMES: After 11–19 months, 29% of the trans feminine individuals had plasma estradiol concentrations within the treatment target. RESULTS: The plasma concentration of estradiol varies greatly during FHT. Plasma levels of estrogen were within the treatment target after 11–19 months of treatment, whereas 100% had concentrations within the reference range for premenopausal cis-women. Furthermore, plasma concentrations of lipids and hematological parameters approached female reference ranges after 11 months of FHT. CLINICAL IMPLICATIONS: The target levels of plasma estradiol concentrations during FHT could be expanded, making the wanted physiological changes easier to obtain. STRENGTHS & LIMITATION: This cohort study included 99 AMAB individuals and biochemical evaluation was possible in 67 individuals. Only one individual was lost during follow-up. However, the follow-up period was limited making evaluation of long-term side effects impossible. CONCLUSION: Plasma concentration of estradiol varies greatly during guideline based FHT, making plasma estradiol levels within the target level difficult to attain. JA Hojbjerg, AD Højgaard, A-M Hvas. Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals. Sex Med 2021;10:100472. Elsevier 2021-12-27 /pmc/articles/PMC8847821/ /pubmed/34968811 http://dx.doi.org/10.1016/j.esxm.2021.100472 Text en Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Hojbjerg, Johanne Andersen Højgaard, Astrid Ditte Hvas, Anne-Mette Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title | Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title_full | Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title_fullStr | Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title_full_unstemmed | Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title_short | Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals |
title_sort | biochemical changes during the first year of feminizing hormone therapy in transfeminine individuals |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847821/ https://www.ncbi.nlm.nih.gov/pubmed/34968811 http://dx.doi.org/10.1016/j.esxm.2021.100472 |
work_keys_str_mv | AT hojbjergjohanneandersen biochemicalchangesduringthefirstyearoffeminizinghormonetherapyintransfeminineindividuals AT højgaardastridditte biochemicalchangesduringthefirstyearoffeminizinghormonetherapyintransfeminineindividuals AT hvasannemette biochemicalchangesduringthefirstyearoffeminizinghormonetherapyintransfeminineindividuals |